
Cerenome reports US$0.7M CNSide revenue with trial data due in 2027
The US$20M facility carries interest and royalties, with future funding conditional ahead of mid-2027 cancer trial readouts.

Trading continues on Nasdaq and the TSX as the cannabis producer faces a consecutive-day bid-price test to regain compliance.

The US$20M facility carries interest and royalties, with future funding conditional ahead of mid-2027 cancer trial readouts.

The Ghana producer faces a Nov. 30 deadline to secure at least US$100 million in new funding and plans a January turnaround update.
New controlled event rates expand the avexitide readout, while the company still targets a year-end FDA application.
The balance excludes customer deposits, and the weekly post discloses no sale proceeds or average execution price.

The Financial Times identifies Amazon as the customer, while Fermi says a definitive long-term lease remains under negotiation.

The new supplies work with existing pumps, with a U.S. launch planned for the first half of 2027 and access limited to pharmacy benefits.

The applications follow a Phase 3 trial showing 27 per cent fewer painful crises versus placebo, with regulatory action expected in 2027.

A one-time gain is expected to exceed fourth-quarter operating expenses, while full-year guidance still calls for a loss.
Convertible-note principal stood at US$486.5 million, with about 16,116 bitcoin pledged as the company evaluates operating businesses.
The Alberta proposal carried an estimated US$30M to US$35M cost, while token revaluation drove the quarterly profit.
Natural graphite capacity could grow 20 per cent as China retains its dominance and Western tungsten projects face commissioning milestones.
The Grand Est site will recover cobalt, nickel and copper from black mass, but Veolia disclosed no investment cost or earnings forecast.
Selective sampling identified a new skarn target south of Lamb Mountain, but GoldHaven has not dated follow-up work.
Omineca would retain a 50 per cent carried interest and receive half the recovered gold at a base cost of C$1,000 an ounce.
Uranium sales costs averaged US$87.22 per pound, while the producer awaits Texas approvals for extraction targets before year-end.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The lender becomes its largest shareholder with 9.9 per cent, while the Okanjande stream expands to cover all future production.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
September liquidity of US$145.4 million is forecast to last into late 2028, beyond the expected ReVeRA-301 trial readout.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
Both headline growth rates compare with Q2, while Columbiana billing is expected to start in January 2027.
The existing 165 million USDT balance remains due in 2027, while eligible positive net derivatives value can count toward collateral requirements.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
OPG is reassessing Darlington's first SMR budget and schedule, with its assessment due to be substantially complete by mid-2027.

Prepayments will help fund U.S. enrichment capacity, with enough HALEU for up to five Aurora powerhouses over multiple years.

The proposed 1 GW facility accounts for most of the announced budget, but ReNew has disclosed neither financing terms nor a delivery date.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
International medical sales supplied 59 per cent of quarterly revenue, while gross margin and adjusted EBITDA declined sequentially.

Canada and Germany have completed competition reviews, Curaleaf says, while its offer remains outstanding until Dec. 4.

The board accepted its committee's recommendation on Oct. 26, citing the harvest, a stronger outlook and debt repayment.

The submission draws on studies involving more than 1,000 participants, with a first-half 2027 launch still subject to FDA approval.